Skip to main content

Table 2 Clinical outcomes of patients with middle to lower third rectal adenocarcinoma receiving neoadjuvant concurrent chemoradiotherapy followed by trans-anal total mesorectal excision assisted by single port laparoscopic surgery

From: Neoadjuvant concurrent chemoradiotherapy followed by transanal total mesorectal excision assisted by single-port laparoscopic surgery for low-lying rectal adenocarcinoma: a single center study

  n (%)
Pathologic T stages
 ypT0 5 (21.74)
 ypT1 5 (21.74)
 ypT2 9 (39.13)
 ypT3 4 (17.39)
Pathologic N stages
 ypN0 19 (82.61)
 ypN1 4 (17.39)
Pathologic response
 Complete response 5 (21.74)
 Partial response 18 (78.26)
 No response 0 (0.00)
Distal margin status
 R0 23 (100.00)
 R1 0 (0.00)
 R2 0 (0.00)
Circumferential resection margin status
 R0 21 (91.30)
 R1 2 (8.70)
 R2 0 (0.00)
Lymph nodes harvested, mean (range) 15.3 (6-42)
Operative time (min), mean (range) 366 (240-480)
Estimated blood loss (mL), mean (range) 159 (10-650)
Conversion 1 (4.35)
30-days complication 5 (21.74)
Mobilization of splenic flexure 19 (82.61)
Inter-sphincter resection 14 (60.87)
Type of anastomosis (hand-sewn) 14 (60.87)
Type of anastomosis (stapled) 9 (39.13)
Length of hospital stays (days), mean (range) 8.4 (6-22)